Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.

Romeo MAL, Martinelli V, Dalla Costa G, Colombo B, De Feo D, Esposito F, Ferrè L, Guaschino C, Guerrieri S, Liberatore G, Martinelli Boneschi F, Merlini A, Messina M, Messina R, Nuara A, Preziosa P, Radaelli M, Rocca MA, Rodegher M, Sangalli F, Strambo D, Moiola L, Comi G.

Acta Neurol Scand. 2018 Nov;138(5):447-453. doi: 10.1111/ane.12999. Epub 2018 Jul 22.

PMID:
30033621
2.

Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.

Llufriu S, Rocca MA, Pagani E, Riccitelli GC, Solana E, Colombo B, Rodegher M, Falini A, Comi G, Filippi M.

Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838. [Epub ahead of print]

PMID:
29683371
3.

Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.

Riccitelli GC, Pagani E, Rodegher M, Colombo B, Preziosa P, Falini A, Comi G, Filippi M, Rocca MA.

Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091. [Epub ahead of print]

PMID:
29173009
4.

Slowly progressing varicella zoster brainstem encephalitis complicating Ramsay Hunt syndrome in an immunocompetent patient: case report and review of the literature.

Ricigliano VAG, Saraceno L, Cavalli M, Rodegher M, Meola G.

J Neurovirol. 2017 Dec;23(6):922-928. doi: 10.1007/s13365-017-0575-3. Epub 2017 Sep 13.

PMID:
28905216
5.

Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations.

d'Ambrosio A, Hidalgo de la Cruz M, Valsasina P, Pagani E, Colombo B, Rodegher M, Comi G, Filippi M, Rocca MA.

Hum Brain Mapp. 2017 Dec;38(12):6005-6018. doi: 10.1002/hbm.23805. Epub 2017 Sep 7.

PMID:
28881433
6.

Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.

Hidalgo de la Cruz M, d'Ambrosio A, Valsasina P, Pagani E, Colombo B, Rodegher M, Falini A, Comi G, Filippi M, Rocca MA.

Mult Scler. 2018 Aug;24(9):1183-1195. doi: 10.1177/1352458517717807. Epub 2017 Jun 28.

PMID:
28657428
7.

Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.

Martinelli V, Dalla Costa G, Messina MJ, Di Maggio G, Sangalli F, Moiola L, Rodegher M, Colombo B, Furlan R, Leocani L, Falini A, Comi G.

Acta Neurol Scand. 2017 Nov;136(5):454-461. doi: 10.1111/ane.12761. Epub 2017 Apr 9.

PMID:
28393349
8.

Dysregulation of MS risk genes and pathways at distinct stages of disease.

Srinivasan S, Di Dario M, Russo A, Menon R, Brini E, Romeo M, Sangalli F, Costa GD, Rodegher M, Radaelli M, Moiola L, Cantarella D, Medico E, Martino G, Furlan R, Martinelli V, Comi G, Farina C.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 16;4(3):e337. doi: 10.1212/NXI.0000000000000337. eCollection 2017 May.

9.

Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.

Rocca MA, Valsasina P, Leavitt VM, Rodegher M, Radaelli M, Riccitelli GC, Martinelli V, Martinelli-Boneschi F, Falini A, Comi G, Filippi M.

Mult Scler. 2018 Apr;24(4):459-471. doi: 10.1177/1352458517699875. Epub 2017 Mar 15.

PMID:
28294693
10.

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.

Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, Candrian U, Messina MJ, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V.

Mult Scler. 2018 Feb;24(2):167-174. doi: 10.1177/1352458517694089. Epub 2017 Feb 1.

PMID:
28273776
11.

Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.

D'Ambrosio A, Pagani E, Riccitelli GC, Colombo B, Rodegher M, Falini A, Comi G, Filippi M, Rocca MA.

Mult Scler. 2017 Aug;23(9):1194-1203. doi: 10.1177/1352458516674567. Epub 2016 Oct 19.

PMID:
27760859
12.

Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes.

Rocca MA, Vacchi L, Rodegher M, Meani A, Martinelli V, Possa F, Comi G, Falini A, Filippi M.

Brain Imaging Behav. 2017 Oct;11(5):1238-1247. doi: 10.1007/s11682-016-9591-9.

PMID:
27714550
13.

Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.

Vacchi L, Rocca MA, Meani A, Rodegher M, Martinelli V, Comi G, Falini A, Filippi M.

Mult Scler. 2017 Apr;23(4):577-587. doi: 10.1177/1352458516656809. Epub 2016 Jul 11.

PMID:
27354020
14.

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.

Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.

Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26.

PMID:
27230789
15.

The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective.

Messina MJ, Dalla Costa G, Rodegher M, Moiola L, Colombo B, Comi G, Martinelli V.

Mult Scler Int. 2015;2015:353828. doi: 10.1155/2015/353828. Epub 2015 Dec 15.

16.

Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes.

Dalla Costa G, Passerini G, Messina MJ, Moiola L, Rodegher M, Colombo B, Locatelli M, Comi G, Furlan R, Martinelli V.

J Neuroimmunol. 2015 Dec 15;289:62-7. doi: 10.1016/j.jneuroim.2015.10.009. Epub 2015 Oct 19.

PMID:
26616872
17.

Myeloid cells as target of fingolimod action in multiple sclerosis.

Di Dario M, Colombo E, Govi C, De Feo D, Messina MJ, Romeo M, Sangalli F, Moiola L, Rodegher M, Martino G, Martinelli V, Comi G, Farina C.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 4;2(6):e157. doi: 10.1212/NXI.0000000000000157. eCollection 2015 Dec.

18.

Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.

Rocca MA, Meani A, Riccitelli GC, Colombo B, Rodegher M, Falini A, Comi G, Filippi M.

Mult Scler. 2016 Aug;22(9):1144-53. doi: 10.1177/1352458515614407. Epub 2015 Oct 22.

PMID:
26493126
19.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, Colombo B, Keller Sarmiento IJ, Martinelli V, Leocani L, Martinelli Boneschi F, Comi G, Esposito F.

Neurol Sci. 2016 Feb;37(2):235-42. doi: 10.1007/s10072-015-2392-x. Epub 2015 Oct 16.

PMID:
26474875
20.

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database.

Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.

PMID:
26362907

Supplemental Content

Loading ...
Support Center